Terminated PHASE2 INTERVENTIONAL 1-arm NCT01823679

Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin

A Phase 2 Study of Capecitabine in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin

Sponsor: National Cancer Institute (NCI)

Conditions Recurrent Skin Cancer Squamous Cell Carcinoma of the Skin

Updated 7 times since 2017 Last updated: Mar 15, 2018 Started: Mar 31, 2013 Primary completion: May 31, 2014 Completion: May 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low accrual

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

This PHASE2 trial investigates Recurrent Skin Cancer and Squamous Cell Carcinoma of the Skin and is currently terminated or withdrawn. National Cancer Institute (NCI) leads this study, which shows 7 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
May 2017 — Jun 2018 [monthly]

Terminated PHASE2

▶ Show 2 earlier versions

Feb 2017 — May 2017 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Mar 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
Stanford University

Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stanford, United States